Почетна › Мијелофиброза › Тексас › Houston
Kliničke studije za Мијелофиброза u gradu Houston, TX
20 studija za Мијелофиброза traži učesnike na lokacijama u gradu Houston i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Тражи се учесникФаза 1
- University of Texas M. D. Anderson Cancer Center, Houston
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Тражи се учесникФаза 3
- MD Anderson Cancer Center, Houston
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Тражи се учесникФаза 1
- MD Anderson Cancer Center, Houston
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Тражи се учесникФаза 3
- MD Anderson Cancer Center, Houston
- The University of Utah-Huntsman Cancer Institute, Houston
- LUMI Research, Houston
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Тражи се учесникФаза 2
- GSK Investigational Site, Houston
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Тражи се учесникФаза 1
- The University of Texas, MD Anderson Cancer Center, Houston
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
Тражи се учесникФаза 1
- Site US10, Houston
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Тражи се учесникФаза 1/2
- MD Anderson, Houston
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
Тражи се учесникФаза 1
- The University of Texas MD Anderson Cancer Center, Houston
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Тражи се учесникФаза 1/2
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Тражи се учесникФаза 1/2
- MD Anderson Cancer Center, Houston
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
Тражи се учесникФаза 2
- MD Anderson Cancer Center, Houston
Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Тражи се учесникФаза 1/2
- MD Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Тражи се учесникФаза 1
- MD Anderson Cancer Center, Houston
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Тражи се учесникФаза 1
- Md Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Тражи се учесникФаза 2
- MD Anderson, Houston
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Тражи се учесникФаза 2
- MD Anderson, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Тражи се учесникОпсервациона студија
- Massive Bio SYNERGY-AI site, Houston
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Тражи се учесникФаза 3
- U.T. MD Anderson Cancer Center, Houston
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
Тражи се учесникФаза 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Studije za Мијелофиброза u drugim gradovima
- New York City, NY21 студија
- Boston, MA13 студија
- Durham, NC13 студија
- Columbus, OH12 студија
- Seattle, WA12 студија
- Tampa, FL11 студија
- Nashville, TN11 студија
- Miami, FL11 студија
- Salt Lake City, UT11 студија
- Ann Arbor, MI10 студија
- Atlanta, GA10 студија
- Baldwin Park, CA10 студија
Ostale studije u gradu Houston
- Немалоклетни карцином плућа143 студија
- Рак дојке126 студија
- Рак (све врсте)124 студија
- Колоректални карцином101 студија
- Метастатски карцином100 студија
- Рак јајника90 студија
- Akutna mijeloidna leukemija88 студија
- Рак плућа78 студија
- Рак простате73 студија
- Карцином ендометријума69 студија
- Меланом61 студија
- Рак панкреаса59 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.